中國泰凌醫藥集團始創于1995年，是一家集研發、生產、銷售為一體的國際化制藥集團公司，在香港聯合交易所主板上市（股份代號：01011.HK）。集團總部位于香港，在上海設有投資及營銷管理中心，在北京設有研發及醫學事務中心，在蘇州、泰州、長沙及瑞士建有生產基地，擁有10余家全資或控股的生產及銷售公司。
集團的核心產品覆蓋了腫瘤及血液系統疾病、骨代謝疾病、消化系統疾病、中樞神經系統疾病、呼吸系統疾病等多個治療領域，現由CSO招商團隊全面轉型為自營銷售推廣團隊。
泰凌醫藥以“服務健康生命”為使命，以誠信為基石，以創新為動力，追求卓越，以人為本，積極引進優秀的人才，立志成為卓越的醫藥健康企業，為人類的健康事業做出貢獻。
China NT Pharma Group Company Limited, founded in1995, a comprehensive listed pharmaceutical factory engaged in investment, R&D, production, marketing and promotion of medicines and new medicinal technologies (Stock Code: 01011. HK).Headquartered in Hong Kong, with marketing、research and medical business center based in Shanghai, Beijing and Guangzhou. Our main pharmaceutical manufacturing plants located in Suzhou, Taizhou, Changsha and Switzerland. Currently NT Pharma Group has more than 10 subsidiaries.
We focus on development of core products covering tumor and Hematological system, central nervous system, chronic, bone metabolic, generic pharmaceutical and other therapeutic fields. According to our strategy, now we have fully transformed into self-management model.
With the mission of “serving healthy life”, we take credibility as the cornerstone, innovation as the driving force, strive for excellence, and focused on human resources with talent，determined to become an excellent medical &health enterprise and contribute to human health.
歡迎訪問公司網站：http://www.ntpharma.com/